Financial Summary (All financials)
| In millions of CNY, except per share items | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 |
| Revenues | 19,659.5 | 15,736.9 | 13,525.4 | 11,295.5 | 7,182.8 | 6,719.1 | 10,732.9 | 11,760.8 |
| Revenue growth | 24.9% | 16.4% | 19.7% | 57.3% | 6.9% | -37.4% | -8.7% | -517.9% |
| Cost of goods sold | 17,250.1 | 13,443.3 | 11,232.8 | 9,539.0 | 6,420.5 | 6,773.4 | 10,271.5 | 9,214.4 |
| Gross profit | 2,409.3 | 2,293.5 | 2,292.6 | 1,756.5 | 762.3 | -54.4 | 461.3 | 2,546.4 |
| Gross margin | 12.3% | 14.6% | 17.0% | 15.6% | 10.6% | -0.8% | 4.3% | 21.7% |
| Selling, general and administrative | 1,514.0 | 1,058.3 | 1,246.4 | 954.3 | 765.2 | 901.6 | 509.8 | 457.8 |
| Research and development | 160.1 | 175.5 | 148.5 | 139.7 | 88.3 | 86.4 | 68.9 | 63.8 |
| EBITA | 730.8 | 924.1 | 906.1 | 668.1 | -90.3 | -1,833.4 | -721.4 | 1,933.8 |
| EBITA margin | 3.7% | 5.9% | 6.7% | 5.9% | -1.3% | -27.3% | -6.7% | 16.4% |
| Amortization of intangibles | 2.8 | 3.0 | 2.3 | 2.4 | 3.0 | 4.6 | 4.0 | 3.6 |
| EBIT | 727.9 | 921.1 | 903.8 | 665.7 | -93.4 | -1,838.0 | -725.4 | 1,930.2 |
| EBIT margin | 3.7% | 5.9% | 6.7% | 5.9% | -1.3% | -27.4% | -6.8% | 16.4% |
| Pre-tax income | 398.6 | 842.9 | 771.8 | 520.0 | -441.5 | -1,561.6 | -514.3 | 2,027.9 |
| Income taxes | 98.5 | 123.3 | 157.3 | 73.4 | -15.0 | 100.6 | 57.8 | 252.7 |
| Tax rate | 24.7% | 14.6% | 20.4% | 14.1% | 3.4% | | | 12.5% |
| Earnings from continuing ops | 300.1 | 683.7 | 515.9 | 346.6 | -473.7 | -1,662.3 | -572.1 | 1,775.2 |
| Earnings from discontinued ops | | | | | | | 7.8 | -19.8 |
| Net income | 300.1 | 683.7 | 515.9 | 346.6 | -473.7 | -1,662.3 | -564.3 | 1,755.4 |
| Net margin | 1.5% | 4.3% | 3.8% | 3.1% | -6.6% | -24.7% | -5.3% | 14.9% |
| |
| Diluted EPS | $46,894,531.25 | $46,860,795.07 | $48,714,353.16 | $48,339,888.42 | ($2.35) | ($8.53) | ($3.43) | $32,946,937.64 |
| Shares outstanding (diluted) | 0.0 | 0.0 | 0.0 | 0.0 | 201.6 | 194.9 | 167.0 | 0.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|